SLC5A2 and heart failure: As of June 2023, 13 large-scale trials involving >90,000 participants, including the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) and Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF), explored SGLT-2 inhibitors in type-2 diabetes, HF, and kidney disease.